# EXHIBIT 134

#### **Attachment**

With regard to Ranking Member McCaskill's July 26, 2017 letter, Endo provides the following responses:

1. Please describe any suspicious order monitoring program Endo and its subsidiaries have implemented, including efforts to monitor, investigate, or report suspicious transactions between its distributors and pharmacies and efforts to analyze information related to "chargeback" requests;

As a manufacturer of controlled substances, including both branded and generic opioid products, Endo's (the "Company") operating companies, Par Pharmaceutical ("Par") and Endo Pharmaceuticals ("Endo"), maintain robust, highly specialized suspicious order monitoring ("SOM") programs, staffed by the Par DEA Compliance and Endo Customer Service teams.


### Par's SOM Program

#### Efforts to Monitor for Suspicious Opioid Orders

Par, which manufactures the Company's generic opioid product, uses a cloud-based, third party algorithm tool to evaluate To meet the applicable Controlled Substances Act ("CSA") and Drug Enforcement Administration ("DEA") requirements, Par's SOM program is designed to identify orders of unusual size, frequency or pattern. This process includes two main elements:



Par conducts customer due diligence, requiring customers to complete questionnaires regarding their SOM programs, and provide certain accompanying documentation.



#### Efforts to Investigate and Report Suspicious Orders

When an order is identified by the algorithm as an order of interest, or reaches the the order is placed on hold pending review by a member of the Par DEA Compliance team. In investigating held/pended orders, the Par DEA Compliance team will

, and ie tion

If an order is rejected and deemed suspicious, based on the Par DEA Compliance team's review, the order is not shipped and it is reported to the DEA Field Office in accordance with the regulatory requirements.

#### Endo's SOM Program

Endo, which manufactures the Company's two branded opioid products, utilizes a customized suspicious order management validation software tool to evaluate individual orders, based on quantity, size, and frequency ("OSF"). Customers' is used to calculate a customized on hold, pending further investigation by the Endo Customer Service team.

Cleared orders are communicated to Endo's highly-regarded third-party logistics provider (the "3PL""), that assists Endo with the warehousing and distribution of its Schedule II opioid products. Pursuant to contractual agreements, the 3PL maintains an active and valid registration with the Drug Enforcement Administration ("DEA") to engage in the distribution of Endodirected orders of controlled substances, to DEA-registered entities – predominantly, wholesalers. As a DEA-registered distributor, the 3PL is required under DEA's regulations (21 CFR 1301.74(b)) to have a system in place to identify and subsequently report suspicious orders of controlled substances. The 3PL has developed and implemented a proprietary and

confidential, highly-customized Suspicious Order Monitoring ("SOM") program, which evaluates orders for controlled substances received by the 3PL.

The 3PL's SOM tool uses a sophisticated algorithm to evaluate orders. The metrics used in the algorithm include the criteria listed in DEA's regulations (volume, pattern, frequency). Moreover, the algorithm also utilizes additional data points and to detect orders that require additional evaluation prior to distribution. These "orders of interest" are scrutinized and investigated by the 3PL's regulatory affairs department.

If an order of interest is ultimately not determined to be a suspicious order, the order is released and shipped to the customer. If, however, the investigation reveals that the order of interest is a suspicious order, the order is not shipped and DEA and Endo are immediately notified. All decisions made as part of the 3PL's SOM are documented by the 3PL.

2. Please provide any questionnaires Endo and its subsidiaries have sent to distributors regarding their anti-diversion and compliance efforts, and any responses to these questionnaires Endo and its subsidiaries have received, since January 2012.

In response to Item 2, the Company is producing SOM questionnaire forms sent to distributor customers and customers' questionnaire responses, including accompanying documentation. These documents bear the BATES range ENDO\_HSGAC\_000001 through ENDO\_HSGAC\_0002754.



3. Please provide any other formal correspondence Endo and its subsidiaries have sent to or received from distributors concerning their obligations to monitor, investigate, and report suspicious orders since January 2012.

In response to Item 3, the Company is producing responsive email communications with its distributor customers at ENDO\_HSGAC\_0002755 through ENDO\_HSGAC\_0017945.

4. Using the template in Attachment A or a similar format, please provide a list of all suspicious order notifications Endo and its subsidiaries have provided to DEA regarding opioid orders originating from Missouri since January 2012, including

the date of the notification, the name and address of the ordering pharmacy, distributor, or other customer, the substances ordered, and the strength and quantity of each substance in terms of number of pills, metric measurement of liquids, or the strength and number of doses for pre-packaged single-use items, if available.

The Company, upon current information and belief, did not identify any schedule CII or CIII opioid product orders, originating in Missouri, that required DEA suspicious order notification during this time period.

5. Using the template in Attachment A or a similar format, please provide a list of all Missouri-based pharmacies, distributors, or other customers for which Endo and its subsidiaries have conducted an audit or investigation since January 2012 following indications of suspicious orders, including the date of the audit or investigation, the outcome, and any subsequent actions by Endo and its subsidiaries concerning the customer at issue.

In response to Item 5, the Company is producing the enclosed charts listing Par's (at Exhibit A) and Endo's (at Exhibit B) Missouri-based CII or CIII opioid product orders that were held pending internal review. Similar in format to the Committee-provided template, the charts include the date, customer name, DEA-registered facility address, investigative results, and subsequent action taken. A significant number of the pending order investigations resulted in one of the enclosed outcomes described below and referenced in the charts.



CONFIDENTIAL TREATMENT REQUESTED BY ENDO




Order Date	Outcome/Subsequent Action
2016-09-07 11:33:02	Cleared After Review
2016-09-21 10:43:02	Cleared After Review
2016-10-26 11:38:03 2016-11-30 10:48:03	Cleared After Review Cleared After Review
2016-12-14 14:13:03	Cleared After Review
2017-01-25 00:00:00	Cleared After Review
2017-01-25 00:00:00	Cleared After Review
2017.02.02.02.02	
2017-02-20 00:00:00	Cleared After Review
2017-04-12 00:00:00	Cleared After Review
2017-06-28 00:00:00	Cleared After Review

Case: 1:17-md-02804-DAP Doc #: 1960-28 Filed: 07/23/19 8 of 36. PageID #: 138956 **EXHIBIT A** 



		Case: 1:17-md-02804-DAP Doc #: 1960-28 Filed: 07/23/19 9 of 36. PageID #: 138957	
Cleared After Revier			
Cleared After Review   Cleared After Review			
Cleared After Review	2015-08-04 09:15:09		Cleared After Review
Cleared After Revier			
Quared After Review			
Cleared After Revies 2015-09-16-09:16-09  Cleared After Revies 2015-09-21 14:16:14  Cleared After Revies 2015-12-15-09-15-09  Cleared After Revies 2015-12-15-09-15-09			
Cleared After Review 2015-09-16-09  Cleared After Review 2015-09-21 14:16:14  Cleared After Review 2015-12-15 09:15:09			Cleared After Review
Cleared After Reviet 2015-09-21 14:16:14  Cleared After Reviet 2015-12-15 09:15:09  Cleared After Reviet			
Cleared After Reviet 2015-09-21 14:16:14  Cleared After Reviet 2015-12-15 09:15:09  Cleared After Reviet			
Cleared After Review  1015-12-15 09:15:09  Cleared After Review			
Cleared After Review    1015-09-21 14:16:14			
Cleared After Review    1015-09-21 14:16:14			
Cleared After Review    1015-09-21 14:16:14			
015-12-15 09:15:09 Cleared After Review	015-09-16 09:16:09		Cleared After Review
015-12-15 09:15:09 Cleared After Review			
015-12-15 09:15:09 Cleared After Review			
015-12-15 09:15:09 Cleared After Review			
015-12-15 09:15:09 Cleared After Review			
015-12-15 09:15:09 Cleared After Review			
015-12-15 09:15:09 Cleared After Review	245 22 24 44 45 44		Cl. LAG. D.:
	J15-09-21 14:15:14		Cleared After Review
	015-12-15 09:15:09		Cleared After Review
015-12-16 09:15:09 Cleared After Review			
015-12-16 09:15:09 Cleared After Reviet			
015-12-16 09:15:09 Cleared After Review			
Cleared After Review			
Cleared After Review			
Cleared After Review			
Cleared After Review			
Cleared After Review			
Cleared After Review			
Cleared After Review			
	015-12-16 09:15:09		Cleared After Review
Confider Con	Confide		ISGAC_0017948

Case: 1:17-md-02804-DAP Doc #: 1960-28 Filed: 07/23/19 10 of 36. PageID #: 138958 2016-02-03 09:16:09 Cleared After Review 2016-02-03 09:16:09 Cleared After Review 2014-09-29 13:05:13 Cleared After Review 2014-09-29 13:05:13 Cleared After Review 2014-10-08 15:15:15 Cleared After Review 2014-09-29 13:05:13 Cleared After Review 2014-09-29 13:05:13 Cleared After Review 2014-10-08 15:15:15 Cleared After Review 2015-02-23 17:15:17 Cleared After Review 2017-07-07 00:00:00 Cleared After Review 2017-07-31 00:00:00 Cleared After Review 2014-06-10 09:34:09 Cleared After Review 2014-06-17 10:04:10 Cleared After Review 2014-06-24 09:35:09 Cleared After Review 2016-02-02 15:16:15 Cleared After Review 2017-02-01 00:00:00 Cleared After Review 2017-05-24 00:00:00 Cleared After Review 2013-12-20 09:45:09 Cleared After Review 2014-04-16 16:25:16 Cleared After Review 2014-04-23 14:14:14 Cleared After Review 2014-04-30 13:16:13 Cleared After Review 2014-04-30 13:16:13 Cleared After Review 2014-05-07 12:45:12 Cleared After Review Cleared After Review 2014-05-07 12:45:12 2014-05-14 13:09:13 Cleared After Review 2014-05-14 13:09:13 Cleared After Review 2014-05-21 13:27:13 Cleared After Review 2014-05-21 13:27:13 Cleared After Review 2014-05-28 10:54:10 Cleared After Review 2014-05-28 10:54:10 Cleared After Review Confide SGAC\_0017949



			<u> </u>
2016-06-09 11:15:11			Cleared After Review
014-04-15 19:17:19			Cleared After Review
014-04-22 19:21:19			Cleared After Review
014-06-10 17:47:17 014-06-11 15:22:15			Cleared After Review Cleared After Review
014-06-11 15:22:15			Cleared After Review
14-07-15 09:39:09			Cleared After Review
14 07 13 05.55.05			Ged ed Alter Neview
14-07-16 17:46:17			Cleared After Review
14-07-22 19:25:19			Cleared After Review
14-08-01 12:50:12			Cleared After Review
14-08-08 19:14:19			Cleared After Review
14-09-23 12:15:12			Cleared After Review
14-09-23 12:15:12			Cleared After Review
14-09-24 14:02:14			Cleared After Review
14-10-06 09:15:09			Cleared After Review
14-10-09 17:15:17			Cleared After Review
Confid			18640 0047054
Confid			ISGAC_0017951

2014-10-10 14:15:14	Cleared After Review
2014-10-15 10:16:10	Cleared After Review
2014-10-17 16:15:16	Cleared After Review
2014 10 27 00:15:00	Cleared After Review
2014-10-27 09:15:09	Lieared After Review
2014-11-03 09:15:09 2014-11-05 15:15:15	Cleared After Review Cleared After Review
2014-11-05 15:15:15	Cleared After Review
2014-11-20 17:15:17	Cleared After Review
2014-11-25 16:15:16	Cleared After Review

		_
	Case: 1:17-md-02804-DAP Doc #: 1960-28 Filed: 07/23/19 14 of 36. PageID #: 138962	
2014-12-02 18:15:18		Cleared After Review
2014-12-05 17:15:17		Cleared After Review
2014-12-11 09:15:09		Cleared After Review
2015-03-24 11:15:11		Cleared After Review
2015-04-01 15:15:15		Cleared After Review
2015-04-20 17:15:17		Cleared After Review
2015-07-14 17:15:17		Cleared After Review
2016-02-03 17:16:17		Cleared After Review
2016-04-05 14:15:14		Cleared After Review
2016-05-17 14:15:14		Cleared After Review
2016-05-24 15:15:15		Cleared After Review



#### 64 Stop State Guitcome/Substanent Action 6/27/2014 Cleared After Review 6/27/2014 Cleared After Review 6/27/2014 Cleared After Review 6/27/2014 Cleared After Review 7/7/2014 Cleared After Review 7/11/2014 Cleared After Review 7/11/2014 Cleared After Review 7/11/2014 Cleared After Review 7/18/2014 Cleared After Review 7/18/2014 Cleared After Review 7/18/2014 Cleared After Review 7/18/2014 7/18/2014 Cleared After Review 7/25/2014 Cleared After Review 8/1/2014 Cleared After Review 8/6/2014 Cleared After Review 8/6/2014 Cleared After Review 8/6/2014 Cleared After Review 8/8/2014 Cleared After Review

Confidential Treatment Requested by Endo ENDO\_HSGAC\_0017955

#### Case: 1:17-md-02804-DAP Doc #: 1960-28 Filed: 07/23/19 17 of 36. PageID #: 1389<mark>6</mark>

Ship Date	Guttome/Suberovent Action
8/8/2014	Cleared After Review
8/14/2014	Cleared After Review
8/15/2014	Cleared After Review
8/15/2014	Cleared After Review
8/23/2014	Cleared After Review
8/28/2014	Cleared After Review
9/5/2014	Cleared After Review
0/11/2014	Classed After Devices
9/11/2014	Cleared After Review
9/19/2014	Cleared After Review
9/26/2014	Cleared After Review
10/3/2014	Cleared After Review

Con ENDO\_HSGAC\_0017956

## Subsemp/Subsequent Action Cleared After Review leared After Review Cleared After Review Cleared After Review Cleared After Review Deared After Review Cleared After Review ENDO\_HSGAC\_0017957

Stip Date

10/3/2014

10/14/2014

10/14/2014

10/14/2014

10/14/2014

10/14/2014

10/14/2014

10/17/2014

10/17/2014

10/17/2014

10/17/2014

10/17/2014

10/17/2014

10/24/2014

10/24/2014

10/24/2014

10/24/2014

10/24/2014

10/27/2014

10/30/2014

10/30/2014

10/30/2014

10/30/2014

11/6/2014

11/6/2014

11/6/2014

11/7/2014

11/7/2014

11/7/2014

11/7/2014

11/7/2014

11/7/2014

11/7/2014

11/14/2014

11/14/2014

11/14/2014

11/14/2014

11/14/2014

11/14/2014


11/14/2014


Cor


sementen en	,	
Ship Date		Julcome/Subsequent Action
11/14/2014		Jeared After Review
11/20/2014		Jeared After Review
11/22/2014		Deared After Review
11/22/2014	,	leared After Review
11/22/2014		Deared After Review
11/22/2014		Deared After Review
11/22/2014		Cleared After Review
12/5/2014		Deared After Review
12/5/2014		Deared After Review
12/5/2014		Deared After Review
12/5/2014		leared After Review
12/5/2014		Jeared After Review
12/5/2014		Deared After Review
12/5/2014		Deared After Review
		Deared After Review
12/5/2014	ľ	Jeared Atter Review
13/0/2014		Name of Africa Paralassia
12/8/2014		Cleared After Review
12/12/2014		Cleared After Review
12/12/2014		Jeared After Review
12/12/2014		Jeared After Review
12/12/2014		Deared After Review
12/12/2014		Deared After Review
12/12/2014		leared After Review
12/12/2014		Deared After Review
12/19/2014		Deared After Review
12/19/2014		Cleared After Review
12/19/2014		Deared After Review
12/19/2014		Seared After Review
12/19/2014		Jeared After Review
12/19/2014		Deared After Review
12/19/2014		Jeared After Review
12/19/2014		Deared After Review
12/19/2014		Deared After Review
12/19/2014		
		Deared After Review Deared After Review
12/19/2014		
12/19/2014		Jeared After Review
1/2/2015	· ·	Jeared After Review
		I
		I
		I












	Case: 1:17	-md-02804-D/	AP Doc #: 196	0-28 Filed:	07/23/19	25 of 36.	PageID #: 138	973
3/6/2015								Outpoon Subsection Action
3/6/2015								Cleared After Review
3/6/2015								Cleared After Review
3/6/2015								Cleared After Review
3/10/2015								Cleared After Review
3/10/2015								Cleared After Review
								:
3/13/2015								Cleared After Review
3/13/2015								Cleared After Review
3/13/2015								Cleared After Review
3/13/2015								Cleared After Review
3/13/2015								Cleared After Review
3/13/2015								Cleared After Review





	Case:	1:17-md	l-02804-I	DAP	Doc #:	1960-28	Filed:	07/23/19	28 of 36.	PageID #	: 1389	<b>7</b> 6
54p to le 5/5/2015												Guttome Subection Action  Cleared After Review
5/14/2015												Cleared After Review
6/3/2015												Cleared After Review
0,0,202												
5/44/2015												Stand Ada Budan
6/11/2015												Cleared After Review
7/6/2015												Cleared After Review
7/9/2015												Cleared After Review
7/30/2015												Cleared After Review
,,,35,2525												
8/6/2015												Cleared After Review
8/21/2015												Cleared After Review
8/28/2015												Cleared After Review
8/28/2015												Cleared After Review



